Time filter

Source Type

Bossard C.,University of Nantes | Dobay M.P.,Swiss Institute of Bioinformatics | Parrens M.,Departement de Pathologie | Lamant L.,Departement de Pathologie | And 12 more authors.
Blood | Year: 2014

The extended use of brentuximab-vedotin was reported for CD30+ nonanaplastic peripheralT-celllymphomas(PTCLs)with promising efficacy. CD30 status assessmentis thus a critical factor for therapeutic decision, but the reliability of immunohistochemistry (IHC) in evaluating its expression remains to be defined. This prompted us to investigate the correlation between semiquantitative CD30 protein assessment by IHC andmessengerRNA(mRNA) assessment by micro arraysinacohortof376 noncutaneous PTCLs representative of the main entities. By IHC, CD30 expression was heterogeneous across and within entities and significantly associated with large tumor cell size. In additionto100% anaplastic large-cell lymphomas, 57%ofother PTCL entities were CD30-positive at a 5% threshold. CD30 protein expression was highly correlated to mRNA levels. mRNA levels were bimodal, separating high from low CD30-expressing PTCL cases. Weconclude that IHC is a valuable tool in clinical practice to assess CD30 expression in PTCLs. © 2014 by The American Society of Hematology. Source

Jackson A.E.,Mayo Medical School | Mian M.,Hospital of Bolzano | Mian M.,University of Innsbruck | Kalpadakis C.,University of Crete | And 22 more authors.
Oncologist | Year: 2015

Background. The salivary gland is one of the most common sites involved by nongastric, extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue (MALT). A large series of patients with long-term follow-up has not been documented. This multicenter, international study sought to characterize the clinical characteristics, treatment, and natural history of salivary gland MALT lymphoma. Methods. Patients with biopsy-confirmed salivary gland MALT lymphoma were identified from multiple international sites. Risk factors, treatment, and long-term outcomes were evaluated. Results. A total of 247 patients were evaluated; 76% presented with limited-stage disease. There was a history of autoimmune disorder in 41%, with Sjögren disease being the most common (83%). Fifty-seven percent of patients were initially treated with local therapy with surgery, radiation, or both; 37 of patients were treated with systemic therapy initially, with 47% of those receiving rituximab; and 6% of patients were observed. The median overall survival (OS) was 18.3 years. The median progression-free survival (PFS) following primary therapy was 9.3 years. There was no difference in the outcomes between patients receiving local or systemic therapy in first-line management. On multivariate analysis, age <60 years and low to intermediate international prognostic index were associated with improved OS and PFS; Sjögren disease was associated with improved OS. Conclusion. Salivary gland MALT lymphoma has an excellent prognosis regardless of initial treatment, and patients with Sjögren disease have improved survival. Risks for long-term complications must be weighed when determining initial therapy. © AlphaMed Press 2015. Source

Gilardin L.,Hopital Saint Louis | Gilardin L.,University Pierre and Marie Curie | Copie-Bergman C.,Groupe Henri Mondor Albert Chenevier | Copie-Bergman C.,University Paris Est Creteil | And 16 more authors.
British Journal of Haematology | Year: 2013

Most cases of human immunodeficiency virus (HIV)-associated non-Hodgkin Lymphoma (NHL) are of B-cell origin; T-cell NHLs are rarely reported. Within a single centre prospective cohort of 370 HIV-NHL, 17 (5%) were of T-cell origin (82% male; median age, 39 years). Median CD4+ cell count was 0·194 × 109/l and 41% had undetectable plasma HIV-RNA at lymphoma diagnosis. All patients received combination antiretroviral therapy during chemotherapy. All histological samples were centrally reviewed. The distribution of the histological subtypes differed from the general population with absence of angioimmunoblastic subtype. Lymphoma was disseminated in 14 patients, and seven patients had performance status >2. All patients received full-dose chemotherapy: eight standard and nine intensive regimens. Two patients who received intensive chemotherapy died during therapy. The complete remission rate was 53%; 62·5% with standard therapy and 44% with intensive therapy. After a median follow-up of 7·2 years, the median overall survival was 9·4 months. Most deaths (85%) occurred within the first year following diagnosis, as a consequence of lymphoma progression in 10/13 cases. In this rare but severe complication of HIV infection the use of intensive chemotherapy does not appear to be beneficial for response, with increased toxicity. © 2013 John Wiley & Sons Ltd. Source

Hoertel N.,Service de psychiatrie | Hoertel N.,University of Paris Descartes | Hoertel N.,French Institute of Health and Medical Research | De Maricourt P.,University of Paris Descartes | And 11 more authors.
Journal of Clinical Psychopharmacology | Year: 2014

Background: The present study sought to quantify the generalizability of clinical trial results in individualswith a Diagnostic and StatisticalManual of Mental Disorders, Fourth Edition, diagnosis of social anxiety disorder (SAD) to a large representative community sample. Methods: Data were derived from the 2004-2005 National Epidemiologic Survey on Alcohol and Related Conditions, a large nationally representative sample of 34,653 adults from the US population. We applied a standard set of exclusion criteria representative of pharmacological and psychotherapy clinical trials to all adults with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, diagnosis of SAD (n = 965) in the past 12months and then to a subsample of participants seeking treatment (n = 363). Our aim was to assess how many participants with SAD would fulfill typical eligibility criteria. Results: We found that more than 7 of 10 respondents from the overall SAD sample in a typical pharmacological efficacy trial and more than 6 of 10 participants in a typical psychotherapy efficacy trialwould have been excluded by at least 1 criterion. In addition, more than 8 of 10 respondents seeking treatment for SAD would have been excluded fromparticipation in a typical pharmacological or psychotherapy efficacy trial. Having a current major depression explained a large proportion of ineligibility. Conclusions: Clinical trials should carefully consider the impact of exclusion criteria on the generalizability of their results and explain the rationale for their use. For SAD treatment trials to adequately inform clinical practice, the eligibility rate must be increased through a general relaxation of overly stringent eligibility criteria. Copyright © 2014 Lippincott Williams & Wilkins. Source

Bessede E.,French Institute of Health and Medical Research | Bessede E.,University of Bordeaux 1 | Copie-Bergman C.,Groupe Henri Mondor Albert Chenevier | Copie-Bergman C.,University Paris Est Creteil | And 15 more authors.
Antioxidants and Redox Signaling | Year: 2012

Helicobacter pylori infection plays a crucial role in the pathogenesis of gastric extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT). However, the host response to this infection is also important in the development of the disease. In particular, NADPH oxidases (NOXs) which generate reactive oxygen species are known to induce cell damage possibly leading to carcinogenesis. We analyze for the first time NOX expression in a series of well characterized gastric MALT lymphoma (GML) patients in comparison with controls. Our observation leads to the hypothesis that NOX2 expression is significantly associated with GML. © 2012 Mary Ann Liebert, Inc. Source

Discover hidden collaborations